Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01528111 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
A Phase 1 study, sponsored by Lexicon Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
NCT01528111: Completed Phase 1 study, sponsored by Lexicon Pharmaceuticals.
NCT01528111 is a Phase 1 study that has completed, run by Lexicon Pharmaceuticals. The registered enrollment target is 63 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01528111, a Phase 1 study, has completed, sponsored by Lexicon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
Study Summary
This Phase 1/2a study is intended to assess the safety, tolerability, and effects on intraocular pressure of two dose levels and two dose frequencies of LX7101 when administered topically in the eyes of patients diagnosed with primary open-angle glaucoma or ocular hypertension.
Interventions
- DRUG LX7101 (0.125%)
- DRUG LX7101 (0.25%)
- DRUG LX7101 Vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2012-03 |
| Est. Completion | 2012-06 |
| Phase | Phase 1 |
What the finished NCT01528111 record still lists
NCT01528111 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which LX7101 (0.125%) is the first listed.
NCT01528111 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01528111 about?
NCT01528111 is a clinical study titled "Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension". This Phase 1/2a study is intended to assess the safety, tolerability, and effects on intraocular pressure of two dose levels and two dose frequencies of LX7101 when administered topically in the eyes of patients diagnosed with primary open-angle glaucoma or ocular hypertension.
What is the current status of trial NCT01528111?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2012-03. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01528111?
The interventions under investigation include: LX7101 (0.125%) (DRUG), LX7101 (0.25%) (DRUG), LX7101 Vehicle (DRUG).
Who is sponsoring clinical trial NCT01528111?
This trial is sponsored by Lexicon Pharmaceuticals, which has 56 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01528111's enrollment target sits among peer trials
63 820th of 2000 higher than 1,177 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia